Adherium has obtained US Food and Drug Administration (FDA) clearance for the use of its Hailie Smartinhaler with AstraZeneca’s Airsupra and Breztri inhalation devices.
This clearance is a significant advancement for asthma and chronic obstructive pulmonary disease (COPD) management.
Related: IceCure submits final breast cancer cryoablation data to FDA
The Hailie Smartinhaler solution is a cloud-based platform. It utilises bluetooth-enabled sensors that attach to patient inhalers, providing real-time feedback on medication use.
Airsurpa and Breztri are treatments in respiratory care, providing advanced treatment options for patients.
Airsupra is the first FDA-approved rescue medication for asthma, while Breztri is a triple combination therapy for COPD patients.
The compatibility of Adherium’s Smartinhaler with these devices allows for 100% coverage for triple therapy inhalers in the US market.
Adherium CEO Dr Paul Mastoridis said: “Our mission at Adherium has always been to revolutionise the way respiratory conditions are managed.
“By securing FDA clearance for our Smartinhaler with Airsupra and Breztri, we are bringing that vision to life, offering patients and healthcare providers a powerful tool in the fight against chronic respiratory diseases. This is just the beginning of our journey to transform respiratory care.”
Adherium said the integration of the Hailie Smartinhaler with these AstraZeneca devices enables real-time data collection and insights into medication usage and inhaler technique.
This data can lead to better adherence and personalised treatment plans, potentially improving patient outcomes and treatment efficacy.
Prominent allergist Dr Bill McCann said: “The combination of the Hailie Smartinhaler with Airsupra and Breztri devices represents a leap forward in our ability to treat and manage asthma and COPD.
“This integration allows for a more nuanced understanding of patient needs and the ability to adjust treatments in real time, which is invaluable in achieving optimal patient outcomes.”
